COFFEE TO-1390 → Record 2000)

U.S. DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 689290-227

04 DTO3 Rec'd PCT/PTO 3 0 NOV

U.S.APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. PCT/US03/17559

INTERNATIONAL FILING DATE 4 June 2003 PRIORITY DATE CLAIMED 4 June 2002

•							
TITLE OF INVENTION .							
	CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY						
APPLICANT(S) Martin SHEA and Reinhard EBNER							
Applica	nt herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. 🛛	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.						
2.	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.						
3.	This express request to being national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. 🛛	The US has been elected by the expiration of 19 months from the priority date (Article 31).						
5. 🛛	A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
	a.  is attached herewith (required only if not communicated by the International Bureau).						
	b.  has been communicated by the International Bureau.						
c. 🗵 is not required, as the application was filed in the United States Receiving Office (RO/US)							
6. 🔲	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))						
	a. is attached hereto.						
	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
7. 🖾	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
•	a. are attached hereto (required only if not communicated by the International Bureau).						
	b.  have been communicated by the International Bureau.						
	c.  have not been made; however, the time limit for making such amendments has NOT expired.						
	d. May have not been made and will not be made.						
8., 🗆	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
9. 🖂	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
я́0. 🔲	An English language translation of the annexes to the International Preliminary Examination Report under						
PCT Article 36 (35 U.S.C. 371(c)(5)).							
items 1	1 to 20 below concern other document(s) or information included:						
11. 🔲	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13. 🔲	A FIRST preliminary amendment.						
14. 🔲	A SECOND or SUBSEQUENT preliminary amendment.						
15. 🔲	A substitute specification.						
16. 🔲	A change of power of attorney and/or address letter.						
17. 🔲	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825.						
18. 🛛	A second copy of the published international application under 35 U.S.C. 154(d)(4).						
19. 🔲	second copy of the English language translation of the international application under 35 U.S.C. 15(d)(4).						
20. 🛛	Other items or information: Sequence Listing on Diskette plus statement under 37 C.F.R. 1.821(f)						

Form PTO-1390(Rev.11-2000) page 1 of 2

U.S. APPLICATION NO. (If k	U.S. APPLICATION NO. (If known see 37 6.F.T) 1.8 INTERNATIONAL APPLICATION NO. PCT/US03/17559				ATTORNEY'S DOCKET NUMBER 689290-227			
21.   The following fees are submitted:  Basic National Fee (37 CFR 1.492(a)(1)-(5)):  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO and JPO  \$1110.00								
International prelimin	nary examination fee (37 ( arch Report prepared by the							
International prelimin	nary examination fee (37 orch fee (37 CFR 1.445(a)							
International prelimin but all claims did not	nary examination fee (37 ( satisfy provisions of PCT							
	nary examination fee (37 o ed provisions of PCT Artic							
13	NTER APPROPRIAT	TE BASIC FEE AMOUN	т =	\$ 750.00	5			
	or furnishing the oath or det	declaration later than 20 7 CFR 1.492(e)).	☑ 30	\$ 130.00	2			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$				
Total Claims	36 - 20 =	16	X \$18.00	\$ 288.00	υ [			
Independent Claims	9 - 3=	6	X \$88.00	\$ 528.00	<b>3</b>			
MULTIPLE DEPENDENT	CLAIM(S) (if applicable)	)	+ \$300.00	\$ 0.00				
	TOTAL OF ABOV	VE CALCULATIONS	=	\$ 1695.00	ว 🗌			
Applicant claims sma above are reduced by		CFR 1.27. The fees indicated	-	\$ 848.00	o			
		SUBT	TOTAL =	\$ 848.00	o			
Processing fee of \$130.00 months from the earliest of		\$						
		TOTAL NATIONA	AL FEE =	\$ 848.00	٥			
Fee for recording the encl accompanied by an appro			\$					
		TOTAL FF	EES ENCLOSED =	\$ 848.00	o l			
		Amount to be refunded:	\$					
				charged:	\$			
a. A check no.	a. A check no. in the amount of \$848.00 to cover the above fees is enclosed.							
	b. Please charge my Deposit Account No. <u>03-0678</u> in the amount of \$ to cover the above fees.  A duplicate copy of this sheet is enclosed.							
	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-0678</u> . A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPON	•	Milding Swids.	Date: 30 Nove	emher 2004				
00	102,102		also	alan Grant				
ALAN J. GRA		11.01 (2.01)	SIGNATURE	SIGNATURE				
Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein 5 Becker Farm  ALAN J. GF				1T				
	ew Jersey 07068	NAME						
		33,389						
		ON NUMBER						

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Martin Shea

Serial No:

PCT/US03/17559

Art Unit: Unassigned

Filed:

4 June 2003

**Examiner: Unassigned** 

Title:

CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY

Docket No:

689290-227

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Statement Under 37 CFR 1.821(f)

Sir:

Applicant hereby asserts that the paper Sequence Listing originally filed with this application and the sequence listing being submitted herewith in Computer Readable Form on the accompanying 3.5" diskette are the same and no new matter is being added to the application.

Respectfully submitted,

Alan J. Grant

Reg. No. 33,389

CARELLA, BYRNE, BAIN, GILFILLAN,

CECCHI, STEWART & OLSTEIN 5 Becker Farm Road

Roseland, NJ 07068

Tel. No.: (973) 994-1700